NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $875,750 | -66.2% | 387,500 | -52.1% | 0.00% | -40.0% |
| Q3 2022 | $2,588,720 | -15.8% | 809,200 | 0.0% | 0.01% | -16.7% |
| Q2 2022 | $3,074,480 | +452.3% | 809,200 | +682.6% | 0.01% | +500.0% |
| Q1 2022 | $556,663 | -96.6% | 103,400 | -62.0% | 0.00% | -98.4% |
| Q3 2018 | $16,603,000 | +1000.3% | 272,355 | +1818.0% | 0.06% | +916.7% |
| Q1 2018 | $1,509,000 | -43.6% | 14,200 | -91.8% | 0.01% | -45.5% |
| Q4 2014 | $2,675,000 | -36.5% | 172,556 | -50.5% | 0.01% | -38.9% |
| Q3 2014 | $4,210,000 | -6.4% | 348,813 | -0.6% | 0.02% | -5.3% |
| Q2 2014 | $4,500,000 | +1.7% | 351,053 | -3.9% | 0.02% | 0.0% |
| Q1 2014 | $4,426,000 | +12.6% | 365,174 | +5.5% | 0.02% | +5.6% |
| Q4 2013 | $3,929,000 | +14.3% | 346,157 | +5.2% | 0.02% | +5.9% |
| Q3 2013 | $3,437,000 | +15.9% | 328,938 | +28.1% | 0.02% | +6.2% |
| Q2 2013 | $2,966,000 | – | 256,775 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |